Quinazoline alpha-adrenoreceptor blockers as an adjunct cancer treatment: From bench to bedside

Liam King, David Christie, Wendy Dare, Nijole Bernaitis, Russ Chess-Williams, Catherine McDermott, Amanda Forbes, Shailendra Anoopkumar-Dukie*

*Corresponding author for this work

Research output: Contribution to journalReview articleResearchpeer-review

5 Citations (Scopus)


Drug repurposing has been increasingly used by both researchers and clinicians to identify new cancer treatments. The alpha-1 adrenoreceptor blockers are a class of drugs that have been used for many years in the treatment of hypertension and benign prostatic hyperplasia. Some of the drugs in this class, notably the quinazoline derivatives, have been found to display cytotoxic properties, identifying them as potential options in the treatment of cancer. This review will examine the currently available evidence that investigates the cytotoxic and anti-cancer properties of these agents, the mechanisms behind these properties and how the alpha-1 blockers fit within current cancer therapies. It aims to answer the question of whether these agents can go from the laboratory bench top into cancer clinics.

Original languageEnglish
Article number173831
Number of pages6
JournalEuropean Journal of Pharmacology
Early online date23 Dec 2020
Publication statusPublished - 15 Feb 2021


Dive into the research topics of 'Quinazoline alpha-adrenoreceptor blockers as an adjunct cancer treatment: From bench to bedside'. Together they form a unique fingerprint.

Cite this